12/9/2023 0 Comments Bayer ag stock![]() On the occasion of ECR 2023, Bayer will announce that it will partner with app developers Mediaire, Coreline, and ScreenPoint Medical to strategically expand the offering on Calantic Digital Solutions. These research and development activities to be presented at ECR showcase Bayer's advanced position in digital and AI powered medical imaging, bolstered by the recent acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis as well as the recent launch of Calantic TM Digital Solutions - a new platform delivering access to digital applications, including artificial intelligence enabled programs, for medical imaging. Against this background, another presentation explores available publications evaluating the real-world performance of AI applications to help radiologists and their teams with insights for their clinical practice. While the potential for AI in radiology continues to be realized, the confidence in selecting the best applications and implementing them remains in question. The presence of AI in radiology has grown quickly with over 200 AI applications having received a CE mark for the European market so far. One of Bayer's featured presentations focuses on the potential value of a learning algorithm in liver imaging, a key diagnostic area for Bayer's radiology team. Potential ways to reduce the contrast media dose with the sharper injection bolus profile from the MEDRAD TM Centargo CT Injection System, the latest addition to Bayer's computed tomography portfolio designed to simplify radiology workflows, are the focus of another presentation at ECR.īayer's research and development projects to be presented at ECR also include the topic of artificial intelligence and digital tools and how to leverage their vast potential in medical imaging. The study investigated the dose-response of gadoquatrane compared to a standard dose of gadobutrol, a well-established macrocyclic GBCA. High relaxivity has in general the potential to enable a substantially lower gadolinium (Gd) dose. ![]() Gadoquatrane features high stability as well as high relaxivity, which is a key property for use in contrast-enhanced magnetic resonance imaging (MRI). The presentations reflect Bayer's commitment as a leading company in key radiology areas to accelerate innovation for the benefit of patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).Ī key presentation highlights new clinical data on the novel development compound gadoquatrane, a next generation macrocyclic gadolinium-based contrast agent (GBCA) which is currently in Phase II of clinical development and planned to enter Phase III later this year. Berlin, FebruBayer announced today that new data from the company's advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |